Add listing
    0
    Add listing

    Valuation Lab: Cosmo Valuation Report “No guts, no glory”

    • Monday, June 4, 2018 @ 4:00 pm

    In May, Cosmo’s key pipeline product MethyleneBlue suffered a setback with the FDA issuing a Complete Response Letter (non-approval) and surprisingly requiring a second phase III trial to gain US approval. We conservatively push back US approval by ~3 years. EU filing remains unchanged for Q4 2018 with approval expected at the end of 2019. MethyleneBlue, with unchanged global peak sales of USD 700+ mn, should be transformational for Cosmo. Rifamycin SV/Rifafalk is likely the most underestimated pipeline product with US and EU approval in its first indication for travelers’ diarrhea expected in Q4 2018.

    Key catalysts include:

        • Rifamycin SV/Rifafalk US & EU approval travelers’ diarrhea (Q4 2018)
        • MethyleneBlue EU filing colonoscopy (Q4 2018)
        • Remimazolam US filing procedural sedation (Q4 2018/Q1 2019)

    Read the full report below.

    You may also be interested in